Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2004 / Article

Review | Open Access

Volume 1 |Article ID 598207 | https://doi.org/10.1093/ecam/neh026

Hiromi Kobayashi, Kuniaki Takahashi, Nobuyuki Mizuno, Haruo Kutsuna, Masamitsu Ishii, "An Alternative Approach to Atopic Dermatitis: Part II—Summary of Cases and Discussion", Evidence-Based Complementary and Alternative Medicine, vol. 1, Article ID 598207, 11 pages, 2004. https://doi.org/10.1093/ecam/neh026

An Alternative Approach to Atopic Dermatitis: Part II—Summary of Cases and Discussion

Received07 Apr 2004
Accepted10 May 2004

Abstract

In the first part of this Review, we presented case-series where Kampo treatment was introduced for those atopic dermatitis (AD) patients who had failed with conventional therapy, in an attempt to prove that there exists a definite subgroup of AD patients for whom Kampo treatment is effective. In this second part, we will first provide the summary of the results for 140 AD patients we treated in 2000. The results suggest that Kampo treatment is effective for more than half of AD patients who fail with conventional therapy. In the Discussion, we will examine the evidential basis for conventional AD therapy and discuss how Kampo treatment should be integrated into the guidelines for AD therapy. We contend that Kampo treatment should be tried before systematic immunosuppressive agents are considered. As each Kampo treatment is highly individualized, it should be regarded more as ‘art’ than technology, and special care should be taken to assess its efficacy in clinical trial.

Copyright © 2004 Hiromi Kobayashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views129
Downloads567
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.